At Granules, we believe in building strategic partnerships based on mutual trust and long lasting relationships.
In 2007, Granules entered into a 50:50 joint venture (JV) with Hubei Biocause China, which manufactures Ibuprofen at a plant in central China. It is one of the premier Ibuprofen manufacturers in China, with a 4,800 TPA installed capacity. The JV ensures a regular supply of raw material to support Granules’ growing penetration into both, OTC & prescription finished dosages.
In 2011, Granules entered into a 50:50 joint venture with Ajinomoto OmniChem, a Belgian company that specializes in contract manufacturing of intermediates and APIs for innovator companies. Granules OmniChem, a multi product API plant located in Vizag, provides an entry into the CRAMS market, without a significant outlay in R&D. Granules OmniChem focuses on complex APIs in therapeutic segments, such as CVS, CNS and oncology.